Home / Resource Library / Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma

Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma

Results of a study involving bendamustine and rituximab for first line MALT lymphoma.